Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-PSMA-11 PET in Metastatic Castration Resistant Prostate Cancer
NCT04716725Phase 2Terminated
- Start
- Sep 2021
- Primary completion
- Sep 2023
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
A Phase 2 trial of gallium ga-68 gozetotide in castration-resistant prostate cancer (CRPC). Started Sep 2021; status: terminated.
02
Drugs
gallium ga-68 gozetotide
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT04716725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04716725.